183 related articles for article (PubMed ID: 22241790)
1. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.
Crago AM; Socci ND; DeCarolis P; O'Connor R; Taylor BS; Qin LX; Antonescu CR; Singer S
Clin Cancer Res; 2012 Mar; 18(5):1334-40. PubMed ID: 22241790
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of multiply recurrent retroperitoneal liposarcoma: A single-center experience.
Masaki N; Onozawa M; Inoue T; Kurobe M; Kawai K; Miyazaki J
Asian J Surg; 2021 Jan; 44(1):380-385. PubMed ID: 33191070
[TBL] [Abstract][Full Text] [Related]
3. High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Wang X; Asmann YW; Erickson-Johnson MR; Oliveira JL; Zhang H; Moura RD; Lazar AJ; Lev D; Bill K; Lloyd RV; Yaszemski MJ; Maran A; Oliveira AM
Genes Chromosomes Cancer; 2011 Nov; 50(11):849-58. PubMed ID: 21793095
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.
Tap WD; Eilber FC; Ginther C; Dry SM; Reese N; Barzan-Smith K; Chen HW; Wu H; Eilber FR; Slamon DJ; Anderson L
Genes Chromosomes Cancer; 2011 Feb; 50(2):95-112. PubMed ID: 21117066
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas.
Fabre-Guillevin E; Coindre JM; Somerhausen Nde S; Bonichon F; Stoeckle E; Bui NB
Cancer; 2006 Jun; 106(12):2725-33. PubMed ID: 16688768
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
7. Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
Jing W; Lan T; Chen H; Zhang Z; Chen M; Peng R; He X; Zhang H
Histopathology; 2018 Jun; 72(7):1145-1155. PubMed ID: 29368794
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
Crago AM; Singer S
Curr Opin Oncol; 2011 Jul; 23(4):373-8. PubMed ID: 21552124
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization.
Nishio J; Iwasaki H; Ishiguro M; Ohjimi Y; Fujita C; Ikegami H; Ariyoshi A; Naito M; Kaneko Y; Kikuchi M
Int J Oncol; 2003 Mar; 22(3):535-42. PubMed ID: 12579306
[TBL] [Abstract][Full Text] [Related]
10. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Changes Associated with Dedifferentiation in Liposarcoma Predict Overall Survival.
Shannon NB; Tan QX; Tan JW; Hendrikson J; Ng WH; Ng G; Liu Y; Tan GHC; Wong JSM; Soo KC; Teo MCC; Chia CS; Ong CJ
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207401
[TBL] [Abstract][Full Text] [Related]
12. The transition of tissue inhibitor of metalloproteinases from -4 to -1 induces aggressive behavior and poor patient survival in dedifferentiated liposarcoma via YAP/TAZ activation.
Shrestha M; Ando T; Chea C; Sakamoto S; Nishisaka T; Ogawa I; Miyauchi M; Takata T
Carcinogenesis; 2019 Oct; 40(10):1288-1297. PubMed ID: 31074490
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
14. miR-193b-Regulated Signaling Networks Serve as Tumor Suppressors in Liposarcoma and Promote Adipogenesis in Adipose-Derived Stem Cells.
Mazzu YZ; Hu Y; Soni RK; Mojica KM; Qin LX; Agius P; Waxman ZM; Mihailovic A; Socci ND; Hendrickson RC; Tuschl T; Singer S
Cancer Res; 2017 Nov; 77(21):5728-5740. PubMed ID: 28882999
[TBL] [Abstract][Full Text] [Related]
15. Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.
Wu YV; Okada T; DeCarolis P; Socci N; O'Connor R; Geha RC; Joy Somberg C; Antonescu C; Singer S
Genes Chromosomes Cancer; 2012 Apr; 51(4):313-27. PubMed ID: 22170698
[TBL] [Abstract][Full Text] [Related]
16. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
[TBL] [Abstract][Full Text] [Related]
17. A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma.
Angeles CV; Velez A; Rios J; Laxa B; Shum D; Ruiz PD; Shen Y; Ostrovnaya I; Gularte-Mérida R; Nacev BA; Dickson MA; Djaballah H; Okada T; Singer S
Clin Cancer Res; 2022 Jan; 28(1):175-186. PubMed ID: 34667024
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical, cytogenetic, and molecular cytogenetic characterization of both components of a dedifferentiated liposarcoma: implications for histogenesis.
Nishio J; Iwasaki H; Nabeshima K; Naito M
Anticancer Res; 2015 Jan; 35(1):345-50. PubMed ID: 25550570
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study.
Li ZK; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2021 Feb; 32(2):210-214. PubMed ID: 33290314
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and histopathological review of dedifferentiated liposarcoma: a comprehensive study of 123 primary tumours.
Mori T; Yamada Y; Kinoshita I; Kohashi K; Yamamoto H; Ito Y; Susuki Y; Kawaguchi K; Nakashima Y; Oda Y
Histopathology; 2022 Feb; 80(3):538-557. PubMed ID: 34699612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
